SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
January 09 2023 - 8:00AM
SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage
biopharmaceutical company with a novel immunotherapy platform that
produces specifically targeted, high-potency, high-avidity,
fully-human polyclonal antibodies without the need for human
donors, announced today that Alexandra Kropotova, MD, Executive
Vice President and Chief Medical Officer, will deliver a
presentation at the Biotech Showcase in San Francisco on Tuesday,
Jan. 10 at 2:30 p.m. PST.
Dr. Kropotova’s presentation, titled: Next Generation
Biologics in Immunology: Solution for Complex Diseases,
will discuss the latest innovations and treatment pathways in
immunology, including an overview of SAB’s novel DiversitAb™
platform. DiversitAb™ is the only platform in the world that
produces fully-human, broadly neutralizing, polyclonal antibodies
utilizing transchromosomic cows. Dr. Kropotova will also present
data from completed clinical trials that indicate SAB’s polyclonal
antibody therapies can provide long-lasting efficacy against
numerous highly mutating pathogens or multiple targets or pathways
at once.
“SAB’s approach is to develop treatments designed to address
multiple dysregulated pathways, multiple disease targets, and
multiple epitopes in one powerful treatment,” said Dr. Kropotova.
“SAB’s groundbreaking DiversitAb™ therapeutic platform and its
promising pipeline developments in influenza, Clostridioides
difficile, type 1 diabetes and other complex disease states with
high unmet patient need is setting a promising new standard for
immunology.”
During the Biotech Showcase, potential partners, collaborators,
and investors who are registered and attending the conference may
request one-on-one appointments with the Company through the
Biotech Showcase partnering platform:
https://informaconnect.com/biotech-showcase/
To schedule an in-person or virtual meeting during J.P. Morgan
week, regardless of attendance or registration, please contact:
SABIR@westwick.com
To learn more about partnering opportunities with SAB
Biotherapeutics, visit:
https://www.sab.bio/partnering-opportunities/
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage
biopharmaceutical company focused on the development of powerful
and proprietary immunotherapeutic polyclonal human antibodies to
treat and prevent infectious diseases and immune and autoimmune
disorders. Our development programs include infectious diseases
resulting from outbreaks and pandemics, as well as immunological,
gastroenterological, and respiratory diseases that have significant
mortality and health impacts on immune compromised patients. SAB
has applied advanced genetic engineering and antibody science to
develop Transchromosomic (Tc) Bovine™. Our versatile DiversitAb™
platform is applicable to a wide range of serious unmet needs in
human diseases. It produces natural, specifically targeted,
high-potency, fully-human polyclonal immunotherapies without the
need for human donors. SAB currently has multiple drug development
programs underway and collaborations with the US government and
global pharmaceutical companies. For more information on SAB,
visit: https://www.SAb.bio and follow SAB on Twitter and
LinkedIn.
Forward-Looking Statements
Certain statements made herein that are not historical facts are
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Forward-looking statements generally are accompanied by words
such as “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “expect,” “should,” “would,” “plan,”
“predict,” “potential,” “seem,” “seek,” “future,” “outlook” and
similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. These
forward-looking statements include, but are not limited to,
statements regarding future events, including the development and
efficacy of our influenza program, C. diff. program, Type 1
Diabetes program, and other discovery programs, the likelihood that
a patent will issue from any patent application, the results,
including timing, of the development of SAB-176, SAB-185 and
SAB-195 (including any IND filing or proposed clinical trials),
financial projections and future financial and operating results
(including estimated cost savings and cash runway), the outcome of
and potential future government and other third-party
collaborations or funded programs (including negotiations with the
DoD).
These statements are based on the current expectations of SAB
and are not predictions of actual performance, and are not intended
to serve as, and must not be relied on, by any investor as a
guarantee, prediction, definitive statement, or an assurance, of
fact or probability. These statements are only current predictions
or expectations, and are subject to known and unknown risks,
uncertainties and other factors which may be beyond our control.
Actual events and circumstances are difficult or impossible to
predict, and these risks and uncertainties may cause our or our
industry’s results, performance, or achievements to be materially
different from those anticipated by these forward-looking
statements. A further description of risks and uncertainties can be
found in the sections captioned “Risk Factors” in our most recent
annual report on Form 10-K, subsequent quarterly reports on Form
10-Q, and other filings with or submissions to, the U.S. Securities
and Exchange Commission, which are available at
https://www.sec.gov/. Except as otherwise required by law, SAB
disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date they
were made, whether as a result of new information, future events,
or circumstances or otherwise.
CONTACTS
Investor Relations:SAbIR@westwicke.com
Media Relations:SAbPR@westwicke.com
SAB Biotherapeutics (NASDAQ:SABSW)
Historical Stock Chart
From Nov 2024 to Dec 2024
SAB Biotherapeutics (NASDAQ:SABSW)
Historical Stock Chart
From Dec 2023 to Dec 2024